Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

Abstract

Denosumab given subcutaneously twice yearly for 36 months was associated with a reduction in the risk of vertebral, nonvertebral, and hip fractures in women with osteoporosis. (ClinicalTrials.gov number, NCT00089791.)